DNA methylation and histone post-translational modifications in atherosclerosis and a novel perspective for epigenetic therapy

被引:0
作者
Liang Zhang
Chenhai Xia
Yongjun Yang
Fangfang Sun
Yu Zhang
Huan Wang
Rui Liu
Ming Yuan
机构
[1] Xijing Hospital,Department of Cardiology
[2] Air Force Military Medical University,Department of Rehabilitation
[3] Tangdu Hospital,undefined
[4] Air Force Military Medical University,undefined
来源
Cell Communication and Signaling | / 21卷
关键词
DNA methylation; Histone post-translational modifications; Epigenetic; Atherosclerosis;
D O I
暂无
中图分类号
学科分类号
摘要
Atherosclerosis, which is a vascular pathology characterized by inflammation and plaque build-up within arterial vessel walls, acts as the important cause of most cardiovascular diseases. Except for a lipid-depository and chronic inflammatory, increasing evidences propose that epigenetic modifications are increasingly associated with atherosclerosis and are of interest from both therapeutic and biomarker perspectives. The chronic progressive nature of atherosclerosis has highlighted atherosclerosis heterogeneity and the fact that specific cell types in the complex milieu of the plaque are, by far, not the only initiators and drivers of atherosclerosis. Instead, the ubiquitous effects of cell type are tightly controlled and directed by the epigenetic signature, which, in turn, is affected by many proatherogenic stimuli, including low-density lipoprotein, proinflammatory, and physical forces of blood circulation. In this review, we summarize the role of DNA methylation and histone post-translational modifications in atherosclerosis. The future research directions and potential therapy for the management of atherosclerosis are also discussed.
引用
收藏
相关论文
共 995 条
[121]  
Tabaee SS(2020)Suberanilohydroxamic acid as a pharmacological Kruppel-Like Factor 2 activator that represses vascular inflammation and atherosclerosis Expert Opin Ther Pat 30 e007134-undefined
[122]  
Chistiakov DA(2017)Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice J Am Heart Assoc. 6 2404-undefined
[123]  
Orekhov AN(2005)Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1 Arterioscler Thromb Vasc Biol 25 241-undefined
[124]  
Bobryshev YV(2010)Enhancing PPARgamma by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice Cardiovasc Res 85 105059-undefined
[125]  
Zaina S(2020)Biocompatible valproic acid-coupled nanoparticles attenuate lipopolysaccharide-induced inflammation Pharmacol Res 160 120567-undefined
[126]  
Heyn H(2021)Histone deacetylase 9 activates IKK to regulate atherosclerotic plaque vulnerability Int J Pharm 601 811-undefined
[127]  
Carmona FJ(2020)Recent developments of HDAC inhibitors: emerging indications and novel molecules Circ Res 127 4577-undefined
[128]  
Varol N(2021)The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease Br J Clin Pharmacol 87 19-undefined
[129]  
Sayols S(2017)Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression Transl Neurodegener 6 3365-undefined
[130]  
Condom E(2004)HDAC2 phosphorylation-dependent Klf5 deacetylation and RARalpha acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs Arthritis Rheum 50 1487-undefined